BevacizumabTreatmentforMeningiomasinNF2:ARetrospectiveAnalysisof15PatientsFabioP.Nunes1,2,VanessaL.Merker1,3,DominiqueJennings4,PaulA.Caruso5,EmmanuellediTomaso6,AlonaMuzikansky7,FredG.BarkerII8,AnatStemmer-Rachamimov6,ScottR.Plotkin1,3*1NeurologyDepartment,MassachusettsGeneralHospital,Boston,Massachusetts,UnitedStatesofAmerica,2GeneticsDepartment,MassachusettsGeneralHospital,Boston,Massachusetts,UnitedStatesofAmerica,3StephenE.andCatherinePappasCenterforNeurooncology,MassachusettsGeneralHospital,Boston,Massachusetts,UnitedStatesofAmerica,4A.A.MartinosCenterforBiomedicalImaging,MassachusettsGeneralHospital,Boston,Massachusetts,UnitedStatesofAmerica,5DepartmentofRadiology,MassachusettsGeneralHospital,Boston,Massachusetts,UnitedStatesofAmerica,6PathologyDepartment,MassachusettsGeneralHospital,Boston,Massachusetts,UnitedStatesofAmerica,7BiostatisticsCenter,MassachusettsGeneralHospital,Boston,Massachusetts,UnitedStatesofAmerica,8NeurosurgicalService,MassachusettsGeneralHospital,Boston,Massachusetts,UnitedStatesofAmericaAbstractBevacizumabtreatmentcanresultintumorshrinkageofprogressivevestibularschwannomasinsomeneurofibromatosis2(NF2)patientsbutitseffectonmeningiomashasnotbeendefined.TodeterminetheclinicalactivityofbevacizumabagainstNF2-relatedmeningiomas,wemeasuredchangesinvolumeofmeningiomasinNF2patientswhoreceivedbevacizumabfortreatmentofprogressivevestibularschwannomas.Aradiographicresponsewasdefinedasa20%decreaseintumorsizebyvolumetricMRIanalysis.Inaddition,wedeterminedtheexpressionpatternofgrowthfactorsassociatedwithtumorangiogenesisinparaffin-embeddedtissuesfrom26unrelatedmeningiomas.Atotalof48meningiomasin15NF2patientswereincludedinthisstudywithamedianfollowuptimeof18months.Avolumetricradiographicresponsewasseenin29%ofthemeningiomas(14/48).Tumorshrinkagewasnotdurable:themediandurationofresponsewas3.7monthsandthemediantimetoprogressionwas15months.Therewasnosignificantcorrelationbetweenpre-treatmentgrowthrateandmeningiomaresponseinregressionmodels.TissueanalysisshowednocorrelationbetweentumormicrovasculardensityandexpressionofVEGFpathwaycomponents.Thisdatasuggeststhat,incontrasttoschwannomas,activationofVEGFpathwayisnottheprimarydriverofangiogenesisinmeningiomas.OurresultssuggestthataminorityofNF2-associatedmeningiomasshrinkduringbevacizumabtherapyandthattheseresponseswereofshortduration.Theseresultsarecomparabletopreviousstudiesofbevacizumabinsporadicmeningiomas.Citation:NunesFP,MerkerVL,JenningsD,CarusoPA,diTomasoE,etal.(2013)BevacizumabTreatmentforMeningiomasinNF2:ARetrospectiveAnalysisof15Patients.PLoSONE8(3):e59941.doi:10.1371/journal.pone.0059941Editor:RussellO.Pieper,UniversityofCalifornia-SanFrancisco,UnitedStatesofAmericaReceivedDecember3,2012;AcceptedFebruary19,2013;PublishedMarch21,2013Copyright:ß2013Nunesetal.Thisisanopen-accessarticledistributedunderthetermsoftheCreativeCommonsAttributionLicense,whichpermitsunrestricteduse,distribution,andreproductioninanymedium,providedtheoriginalauthorandsourcearecredited.Funding:ThisworkwassupportedbyaUnitedStatesNationalInstitutesofHeathgrant(5-T32-GM007748-32)toFPN.Thefundershadnoroleinstudydesign,datacollectionandanalysis,decisiontopublish,orpreparationofthemanuscript.CompetingInterests:Theauthorshavedeclaredthatnocompetinginterestsexist.*E-mail:splotkin@partners.orgIntroductionMeningiomasarethemostcommontypeofbraintumor,accountingfor34%ofallcentralnervoussystemtumors.[1]Despitethehighprevalenceofmeningiomasinthegeneralpopulation,therearecurrentlynomedicaltreatmentsavail-able.[2,3]Forsporadicmeningiomasthatrequireactivetreatment,surgeryandradiationtherapyareusuallyeffective.Meningiomasareevenmorecommoninneurofibromatosis2(NF2)patients,withacumulativeincidenceof80%byage70,[4]andareamajorcauseofmorbidityandmortalityinthesepatients.[5,6]ThelackofeffectivemedicaltherapyformeningiomasrepresentsasignificantchallengeintheclinicalmanagementofNF2patients.Unlikepatientswithsporadictumors,NF2patientsoftenhavemultiplemeningiomas,vestibularschwannomas,andependymomas.Themultiplicityoftumorsmakesurgeryandradiationtherapyforalltumorsimpracticable.Neovascularizationisnecessaryfortumorgrowthbeyond2–3mm,[3]thepointatwhichdiffusionalonebecomesinsufficienttomeetbasictumormetabolicrequirements,[7]andisdrivenbytumorproducedangiogenicfactorssuchasvascularendothelialgrowthfactor(VEGF)thatstimulatethegrowthoftumorcapillaries.BevacizumabisahumanizedmonoclonalantibodythatneutralizestheactivityofVEGF.[8]BevacizumabpreventsthebindingofallVEGFisoformstoVEGFreceptors,andiscurrentlyapprovedbytheFoodandDrugAdministration(FDA)forclinicaluseinrecurrentglioblastoma,metastaticcolorectalcancer,advancednonsquamousnon-smallcelllungcancer,andmetastatickidneycancer(www.fda.govon02/05/2012).WehaverecentlyshownthattreatmentwithbevacizumabcanleadtohearingimprovementandtumorshrinkageinsomeNF2patientswithprogressivevestibularschwannomas.[9]TissueanalysisofschwannomassuggestedactivationoftheVEGFpathwayduetodecreasedexpressionofSEMA3,anangiogenesisinhibitor.Theeffectsofbevacizumabonmeningiomasarenotclear.Todate,twocasereportsandtwocaseserieshavebeenpublishedonbevacizumabuseinintracranialmeningiomas,withanecdotalreportsofmeningiomaresponsetobevacizumab.[10–13]Wepresentherearetrospectiveanalysisoftumorresponsein48intracranialmeningiomasfrom15NF2patientstreatedwithbevacizumabforprogressivevestibularschwannoma.PLOSONE|www.plosone.org1March2013|Volume8|Issue3|e59941MethodsEthicsStatementThisresearchstudywasapprovedbythePartnersHumanResearchCommitteeInstitutionalReviewBoard.Requirementforinformedconsentwaswaivedforthisretrospectiveanalysisofclinicaldata.PatientsBetween2007and2011,atotalof31NF2patientsweretreatedatourcenterusingbevacizumabforprogressivevestibularschwannomas.Ofthese31patients,16alsohadintracranialmeningiomas(55%).TwopatientswereexcludedfromthestudybecauseofincompatibilitybetweentheMRIscanformatperformedatanoutsidefacilityandourvolumetricanalysissoftware.WeincludedoneadditionalNF2patientwhounderwentsurgicalresectionofbilateralvestibularschwannomasandwastreatedusingbevacizumabforasingleprogressivemeningioma.Atotalof48meningiomasand18vestibularschwannomasin15NF2patientswereincludedintheanalysis.Patientsreceivedbevacizumab5mg/kgI.V.every2weeksaspartofclinicalcarefortheirvestibularschwannoma.Higherdosesusedformalignantbraintumors(e.g.,10mg/kg)werenotusedinordertominimizeriskoftoxicity.BrainMRIscanswereperformedwithinabout1monthpriortostartoftreatment,andapproximatelyevery3monthsafterthestartoftreatmenttomonitortumorresponse.AdverseeventswereclassifiedaccordingtotheCommonTerminologyCriteriaforAdverseEvents,version4.VolumetricanalysisCommercialsoftware(Alice;HaydenImageProcessingGroup/ParexelInternationalCorp,Waltham,MA)wasusedtocreatethevolumetricmeasurementsoncontrastenhancedT1-weightedaxialimages.Onceoutliningwascomplete,actualvolumemeasure-mentswerecalculatedinMatlab(TheMathWorks,Natick,MA)bycountingthenumberofvoxelsinagivenimageandmultiplyingthecountbythevolumeofasinglevoxel(ascalculatedusingthein-planeandthrough-planeimageresolution).AmaximumnumberofeighttumorsperpatientcanbemeasuredusingtheAlicesoftware.Inpatientswithmorethan8tumors,volumetricanalysiswasfirstperformedonvestibularschwannomasandthenonmeningiomas(fromlargesttosmallest).Totalintracranialtumorvolumewasdefinedasthesumofthevolumeofallintracranialmeningiomasmeasuredinapatient.WeusedclinicallyindicatedMRIsperformedpriortostartofbevacizumabtherapytodeterminepre-treatmentmeningiomaannualgrowthrate(AGR).Tumorgrowthratewasdefinedas(tumorvolume–baselinetumorvolume)/baselinetumorvolume.Tumorcontoursforvolumetricanalysisweredelineatedbyasingleresearcher(FN)whowasblindedforpatientidentity,timeofscan,andtreatmentstatus(pre-orpost-bevacizumab).AlltumorcontourswereperformedusingT1post-contrastaxialMRIscans.Aftercontourswerecompleted,aneuroradiologist(PC)with10yearsofpost-fellowshipacademicexperiencereviewedthecontours.Fortumorswithindistinctboundaries,theneuroradiol-ogistreviewedaxial,sagittal,andcoronalslicesofpre-andpost-contrastT1-weighted,T2-weighted,diffusion-weightedimages,FLAIR,susceptibility,FIESTAimages,andCTscanswhenavailable.Detailsofthemethodologyusedfordeterminingtumorcontoursareavailableinthesupplementalmaterial(TextS1).DefinitionofimagingresponseAradiographicresponsewasdefinedasadecreaseintumorvolumeof$20%atanytimecomparedwithbaselinevolume.Tumorprogressionwasdefinedasanincreaseinvolumeof$20%whencomparedtobaseline.Stablediseaseincludedallotherresponses.Asustainedradiographicresponsewasdefinedasadecreaseintumorvolumeof$20%whencomparedtobaselineatthetimeofthelastscan.Durationofresponsewasdeterminedasthetimeintervalfromthefirstandlastscansshowingadecreaseinvolume$20%frombaseline,evenifinterimscansdidnotmeetradiographicresponsecriteria.Timetoprogressionwasdefinedasthetimefromfirstdoseofbevacizumabtothefirstscandateinwhichthemeningiomagrew$20%involumecomparedtobaselinemeasurements.RegressionAnalysisWeanalyzedeachoutcomeofinterestonaper-tumorbasisandonaper-patientbasis.Intheper-tumoranalysis,eachtumorwasconsideredanindependenteventwithnoclusteringeffectforindividualpatientswithmultipletumors.Intheper-patientanalysis,weaccountedfortheclusteringeffectofmultipletumorsinindividualpatientsbyusingaregressionmodelthatincludedarandomeffect.Detailsontheregressionmodelusedareavailableinthesupplementalmaterial.Inbothanalyses,wecalculatedthetumorgrowthrateduringthepre-andpost-treatmentperiodsusingallscansavailable(upto4yearsbeforeinitiationoftreatment).Wealsoperformedtheanalysesusingonlythescansinthe12monthsimmediatelypriortoinitiationoftherapytodeterminepre-treatmentannualtumorgrowthrate.Wewantedtodeterminewhetherrelativechangeintumorvolume(percentchangefrombaseline)orabsolutechangeintumorvolumewouldcorrelatewithradiographicresponsetotreatment.Therefore,tumorgrowthratewasrepresentedasrelativechangeintumorvolumefrombaseline(percentageresponse)andasabsolutedifferenceintumorvolumefrombaseline.Wethencorrelatedpre-treatmentgrowthrateswithpost-treatmentgrowthratesusingpatientdemographicinformation(ageatthestartoftreatmentandgender),tumorsizeatbaseline,andtumorlocationascovariates.StatisticalanalysiswasperformedwithSASsoftware(version9.2,SASInstituteInc,NC,USA).APvalueof,.05wasconsideredtobestatisticallysignificant.ImmunohistochemistryInaparallelanalysis,wedeterminedtheexpressionpatternofgrowthfactorsassociatedwithtumorangiogenesisinparaffin-embeddedtissuesof13unrelatedNF2-relatedmeningiomasand13sporadicmeningiomasfromsurgeriesatMassachusettsGeneralHospital.AsimilaranalysisforNF2-relatedandsporadicschwannomaswasreportedpreviously.[9]Fivemicron-thicksec-tionswerecutandimmunostainedwiththefollowingantibodies:CD31(Dako,prediluted),aSMA(Sigma,1:100),VEGF(SantaCruzorNeomarker1:100),VEGFR2,PDGFR-a,PDGFR-b(CellSignaling;1:250,1:100and1:100respectively),Neuropilin-1(Chemicon,1:40),Neuropilin-2(R&DBiosystem,1:500),Sema-phorin3A(Millipore,1:100)andSemaphorin3F(Chemicon1:250).Semiquantitativeanalysiswasperformedbytwoauthorswhoscoredtheintensityofstainingoftumorcellsandbloodvesselsonascalefrom0(nostaining)to3(strongstaining).Forcalculationofmicrovasculardensityanddiameter,CD31labelingwasusedtohighlightvessels.Thequantificationusedatleast5fieldsofconfirmedtumortissueat200xmagnificationwithanaverageof100vesselscountedpersection.AcustomizedsoftwareanalysistoolcompatiblewithImageJ(http://rsb.info.nih.gov/ij/)wasthenusedtodeterminethenumberofvessels,perimeter,theminoraxisofbest-fittedellipse(representativeofthevesseldiameter),andthetotalsurfacecoveredbyvascularspaces.ThesamemethodwasusedsubstitutingeitherVEGFR2orNRP2BevacizumabTreatmentforMeningiomasinNF2PLOSONE|www.plosone.org2March2013|Volume8|Issue3|e59941labelingtodeterminethepercentageofvesselsexpressingtheseVEGFreceptors.Consecutivesectionswereusedtoallowsimilarareasofthetumortobequantifiedinallcases.ResultsAtotalof48meningiomasand18vestibularschwannomasfrom15NF2patients(7men,8women)wereincludedinthisstudy.PatientandtumorcharacteristicsarelistedinTable1.ThemeannumberofMRIscansperpatientusedforanalysisoftumorresponsewas8(range,4–14).Themedianpatientageatthestartoftreatmentwas29.5years(range,16–63years).Themean(median)volumesofmeningiomasandvestibularschwannomasatthebeginningoftreatmentwere6.2cm3(1.9cm3),and9.8cm3(4.3cm3),respectively.Themeanvolumetricgrowthratepriortotreatmentwas11.6%peryearandmedianfollowuptimewas18months(range10to37months).Bevacizumabwasoverallwelltolerated,withonlyfourgrade3adverseevents(hypertension,elevatedliverenzymes,menorrhagia,irregularmenses),andtwograde4events(bothassociatedwithwoundhealingproblems,includingvascularaccesscomplicationsandtracheostomywoundhealingdelays).Aradiographicresponsewasseenin29%oftumors(14/48tumors)usingper-tumoranalysisandwasseenin7%ofpatients(1/15patientsusingaper-patientanalysis)(Figure1).Tumorshrinkagewasnotdurable,withonly5/14respondingmeningi-omasmaintainingaradiographicresponseatthelastfollowup.Themediandurationofmeningiomaresponsewas3.7months(range0to25months),withsixmeningiomashavingasinglescanmeetingcriteriaforradiographicresponse(decreaseinmeningi-omavolume$20%).Overall,29/48meningiomas(60%)progressedduringthestudy.Themediantimetoprogressionwas15monthsonper-tumoranalysis(Figure2)andwas20monthsonper-patientanalysis.Progression–freesurvivalat6-and12-monthswas85%and62%,respectively,onper-tumorbasis.Progression-freesurvivalat6-and12-monthswas93%and79%,respectivelyonper-patientbasis.Theradiographicresponserateforvestibularschwannomasinthiscohortwas39%(7/18tumors)whenusingwholebrainMRIscansandwas44%(8/18tumors)whenusinginternalauditoryTable1.Patientandtumorcharacteristics.CharacteristicsN(%)GenderFemale8(53%)Male7(47%)Age,20y2(13%)20–29y7(47%)30–39y2(13%)40–49y3(20%).50y1(7%)Totalmeningiomasanalyzedperpatient1–2meningiomas8(53%)3–4meningiomas3(20%).4meningiomas4(27%)Medianmeningiomabaselinevolume1.9cm3Distributionofmeningiomavolumeatbaseline(n=48),2cm325(52%)2–10cm316(34%)10–20cm34(8%).20cm33(6%)MeningiomaPre-TreatmentAnnualGrowthRate11.6%(range,-240%to546%)MeningiomalocationOrbital/Skullbase10(21%)Convexity/Falx34(71%)Posteriorfossa4(8%)Medianvestibularschwannomavolumeatbaseline4.3cm3Distributionofvestibularschwannomavolumeatbaseline(n=18),2cm35(27%)2–10cm37(39%)10–20cm33(17%).20cm33(17%)doi:10.1371/journal.pone.0059941.t001BevacizumabTreatmentforMeningiomasinNF2PLOSONE|www.plosone.org3March2013|Volume8|Issue3|e59941Figure1.RadiographicResponseofMeningiomastoBevacizumab.Waterfallplotofbestradiographicresponseforindividualmeningiomas(A)andfortotalmeningiomavolumeinpatients(B).doi:10.1371/journal.pone.0059941.g001BevacizumabTreatmentforMeningiomasinNF2PLOSONE|www.plosone.org4March2013|Volume8|Issue3|e59941canal(3mmslices,nogap).ThedifferenceinresponseratebetweenthecohortofNF2patientswithmeningiomas(44%response)andtheentiretreatedNF2cohortof31patients(55%,datanotshown)wasnotstatisticallysignificant(Fisherexacttwotail=.79).Atotalof47meningiomaswereincludedinregressionanalysestoidentifyclinicalfactorsassociatedwithpost-treatmentgrowthrate.Foronemeningioma,nopre-treatmentscanswereavailableforanalysis.GrowthrateestimatesandstatisticalresultsaresummarizedonTable2.Therewasnosignificantcorrelationbetweenpre-treatmentandpost-treatmentgrowthratesforindividualmeningiomasusingper-tumoranalysis(p=.33).Thisfindingpersistedwhenpre-treatmentgrowthwascalculatedusingonlythe12monthsimmediatelypriortotreatment(p=.79).Therewasnosignificantdifferenceintheresultswhentumorresponsewascalculatedusingabsolutechangeintumorvolumeorpercentchangeintumorvolume(p=0.72).Whenonlymeningiomaswithapre-treamtentgrowthrate$20%andwithbaselinevolume$1cm3wereincludedintheanalysis,radiographicresponsewasseeninonlyoneoutoffivemeningiomas(20%oftumors).Figure3showsthecorrelationbetweenmeningiomabestresponseandpre-treatmentgrowthrate.Intheper-patientanalyses,therewasnosignificantassociationbetweenpre-treatmenttumorgrowthandtumorresponsewhenusingpercentagechangeintumorvolume(p=.23),orabsolutechangeintumorvolume(p=.37).Therewasnodifferenceintheresultswhenpre-treatmentperiodincludedonlythe12monthsimmediatelypriortostartoftherapy.Interestingly,therewasaFigure2.TimetoProgressionforMeningiomaTreatedwithBevacizumab.A.Kaplan-Meiercurvefortimetoprogressionconsideringeachmeningiomaasanindependentevent(per-tumoranalysis).Progressionwasconsideredasanincreaseintumorvolumeof20%ormore.B.Kaplan-Meiercurvefortimetoprogressionusingtotalintracranialmeningiomavolumeforeachpatientasanindependentevent(per-patientanalysis).Timetoprogressionwas15monthsforindividualtumorsand20monthsonper-patientanalysis.Progression-freerateatsixmonthswashigherintheper-patientanalysisat93%,comparedto85%fortheper-tumoranalysis.doi:10.1371/journal.pone.0059941.g002BevacizumabTreatmentforMeningiomasinNF2PLOSONE|www.plosone.org5March2013|Volume8|Issue3|e59941correlationbetweenincreasedpost-treatmentgrowthrateandmalegender(p=.07),andolderage(p=.04).ImmunohistochemicalanalysisofmeningiomasshowednosignificantdifferenceintheexpressionofcomponentsoftheVEGFangiogenesispathway(VEGF,VEGFR2,PDGFR-a,PDGFR-b,neuropilin-1,neuropilin-2,semaphorin3A,andsemaphorin3F)betweensporadicmeningiomasandNF2-associ-atedmeningiomas.MicrovasculardensitywassignificantlygreaterinsporadicmeningiomascomparedtoNF2-relatedmeningiomas(52vessels/mm2vs.32vessels/mm2;t-testp=.01).Therewasnosignificantdifferenceofaverageperimeterordiameterbetweenthetwogroups.DiscussionMedicaltreatmentsformeningiomasaredesperatelyneededforpatientswithmeningiomasthatcannotbeadequatelytreatedwithsurgeryandradiation.Thelistofdrugswithoutaclearbenefitforthesetumorscontinuestogrowandincludestamoxifen,[14]irinotecan,[15]temozolomide,[16]octreotide,[17,18]mifepris-tone,[19]erlotinib,[20]gefitinib,[20]imatinib,[21]andalpha-interferon.[22,23]Althoughinitialresultswithhydroxyureawerepromising,[24]furtherstudiesshowedthatradiographicresponsetohydroxyureainmeningiomasisuncommon.[25,26]OurresultsforNF2-relatedmeningiomasarecomparabletocaseseriesofsporadicmeningiomastreatedwithbevacizumab[12,13].Thesestudies,whichincludedallgradesofmeningiomas,reportedmedianPFSof18226monthsandradiographicresponseratesof027%.BecausemultiplemeningiomasarecommoninNF2patients,weanalyzedourdataonaper-tumorbasisandonaper-patientbasis.Usingper-tumoranalysis,themedianPFSwas15months;usingper-patientanalysis,thePFSwas20months.Theper-tumorradiographicresponseratewas29%inourseriesandexceededtherateinpreviousreports;however,thedurabilityofresponsewasshort.Thiscontrastswiththedurabilityofresponseinschwannoma.[9]Theseresultssuggestthattheclinicalbenefitoftumorshrinkageinourpatientswasminimal.Analysisoftumorgrowthratecanbedeterminedasarelativechange(percentage)intumorvolumefrombaseline,orasanabsolutevolumechangefrombaselinemeasurement.Theuseofrelativechangeisthestandardmethodusedforradiographicresponsetotreatment,whetherlinearmeasurementsorvolumetricanalysismethodsareusedinthestudy.[27]Weanalyzedourdatainbothwaystoaccountforpotentialbiasinthedeterminationofresponseratebasedontumorsizeatbaseline.Relativechangesintumorvolumeareusuallylargerinsmalltumors,leadingtobiasinthestatisticalanalysiswhensmallerandlikelyasymptomatictumorsareincludedinthestudy.Instead,largertumorsaremorelikelytohavelargerabsolutevolumechangesthansmalltumors,evenifonlyasmallpercentagechangeintotalvolumehasoccurred.DuetothebiologyofVEGFinhibitors,suchasbevacizumab,wedecidedtodeterminedresponserateusingbothrelativechangeintumorvolume,aswellasabsolutechangesinvolumefrombaselineforcomparison.Inthisretrospectiveanalysis,neithermeasurementofpre-treatmentgrowthratewasfoundtobesignificantlyassociatedwithtreatmentresponse.Thismaybeduetopoorresponsetotreatmentseeninthisstudy,smallsamplesize,orselectionbiasfromthisretrospectivestudy.Althoughtherewasastatisticalassociationbetweenolderpatientsandmeningiomaresponsetotreatment,therelativeeffectonresponsewassmall,andlikelynotclinicallyrelevant.WehavepreviouslyshownthattreatmentwithbevacizumabcanleadtotumorshrinkageofvestibularschwannomasinpatientsTable2.SummaryofRegressionAnalysisResultsforGrowthRateEstimatesinPer-TumorandPer-PatientModels.Per-tumorAnalysisPer-patientAnalysisFactorPercentageChangeinTumorVolumeAbsoluteChangeinTumorVolumePercentageChangeinTumorVolumeAbsoluteChangeinTumorVolumeParameterEstimatep-valueParameterEstimatep-valueParameterEstimatep-valueParameterEstimatep-valueTumorGrowthbyMonthUsingAllScans20.0530.3320.0110.7220.0660.2320.0250.37TumorGrowthbyMonthUsinglast12months20.0140.790.0020.9420.0160.5620.040.43MaleGenderN/AN/AN/AN/A20.0150.0720.060.33AgeN/AN/AN/AN/A20.00070.0420.0040.09doi:10.1371/journal.pone.0059941.t002BevacizumabTreatmentforMeningiomasinNF2PLOSONE|www.plosone.org6March2013|Volume8|Issue3|e59941withNF2,[9]withfollowupstudyshowingradiographicresponsein55%ofvestibularschwannomas,andhearingimprovementin57%inourcohortof31patients.[28]Inthesesamepatients,radiographicresponsesformeningiomaswereseeninonly29%ofmeningiomasandwereshort-lived..Thedifferenceinresponseratebetweenvestibularschwannomasandmeningiomasdoesnotseemtocorrelatewithdegreeofangiogenesis,sinceexpressionofVEGFinthetumor,expressionofVEGFR2intumorbloodvessels,andmicrovasculardensityaregreaterinmeningiomasthaninvestibularschwannomas.[9]However,immunohistochem-icalanalysisofexpressionoftheVEGFpathwaycomponentsshowsdifferentpatternsinschwannomasandmeningiomas.Inourpreviousstudy,analysisoftheVEGFangiogenesispathwayinschwannomasshowedverylowexpressionofSEMA3(angiogen-esisinhibitor)andapositivecorrelationbetweenVEGF/SEMA3expressionratioandtumormicrovasculardensity;consistentwiththehypothesisthattheangiogenesisinschwannomaswasdrivenbyactivationoftheVEGFpathway.Incontrast,inthisstudy,wefoundarobustexpressionofSEMA3inmeningiomas(NF2associatedandsporadic)andfurthermore;therewasnocorrelationbetweenexpressionofVEGFpathwaycomponentsandtumormicrovasculardensity.ThesefindingssuggestthattheVEGFpathwaymaynotbeanimportantdrivingforceofangiogenesisinmeningiomasandmayexplainthedifferentresponseratesobservedforthetwotypesoftumors.Currently,prospectivestudiesofbevacizumab(NCT01125046)andcombinationofbevacizumabandeverolimus(NCT00972335)areunderwayforpatientswithsporadicrecurrentorprogressivemeningiomas.ConclusionNF2-relatedmeningiomaswerenoteffectivelytreatedbybevacizumabinthisanalysisofNF2patientstreatedfortheirprogressivevestibularschwannomas.Wedidnotidentifyanypredictorsoftumorresponsetobevacizumabinourcohort.PathologicanalysisofcomponentsoftheVEGFangiogenesispathwayandoftumormicrovasculardensityinmeningiomasshowedrobustexpressionofSEMA3(anangiogenesisinhibitorthatwasnotexpressedinschwannomas)andincontrastofourfindingsinschwannomas,therewasnocorrelationbetweenexpressionofVEGFpathwaycomponentsandtumormicrovas-culardensityinmeningiomas.ThesefindingssuggestthattheVEGFpathwaymaynotbeadrivingforceinangiogenesisinmeningiomasandmayexplainlimitedclinicalresponseinmeningiomas.Figure3.MeningiomaBestResponseComparedtoPre-treatmentGrowthRate.Scatter-plotofmeningiomabestresponsevs.relativechangeintumorvolumepriortotreatment.Horizontaldashedlinesshowthresholdforradiographicresponseat20%decreaseintumorvolumeposttreatment,andverticaldashedlineseparatestumorswithpositivegrowthpriortotherapy.doi:10.1371/journal.pone.0059941.g003BevacizumabTreatmentforMeningiomasinNF2PLOSONE|www.plosone.org7March2013|Volume8|Issue3|e59941SupportingInformationTextS1Methodsfordeterminingtumorvolumeandperformingregressionanalysis.(DOC)AcknowledgmentsTheauthorswouldliketothankDrs.RobertMartuzaandStevenGreenbergfortheirguidanceandcriticalreviewofthismanuscript.AuthorContributionsImaginganalysis:FPNPACDJ.Conceivedanddesignedtheexperiments:FPNEdTSRPFGBASR.Performedtheexperiments:FPNVLMDJPACEdT.Analyzedthedata:FPNAMDJASRSRP.Contributedreagents/materials/analysistools:EdTAM.Wrotethepaper:FPNSRPFGBASR.References1.CBTRUS(2012March)CBTRUSStatisticalReport:PrimaryBrainandCentralNervousSystemTumorsDiagnosedintheUnitedStatesin2004222008.2.BriaC,WegnerRE,ClumpDA,VargoJA,MintzAH,etal.(2011)Fractionatedstereotacticradiosurgeryforthetreatmentofmeningiomas.JCancerResTher7:52257.3.NordenAD,DrappatzJ,WenPY(2009)Advancesinmeningiomatherapy.CurrNeurolNeurosciRep9:2312240.4.SmithMJ,HiggsJE,BowersNL,HallidayD,PatersonJ,etal.(2011)Cranialmeningiomasin411neurofibromatosistype2(NF2)patientswithprovengenemutations:clearpositionaleffectofmutations,butabsenceoffemaleseverityeffectonageatonset.JMedGenet48:2612265.5.BaserME,FriedmanJM,AeschlimanD,JoeH,WallaceAJ,etal.(2002)Predictorsoftheriskofmortalityinneurofibromatosis2.AmJHumGenet71:7152723.6.NunesF,MacCollinM(2003)Neurofibromatosis2inthepediatricpopulation.JChildNeurol18:7182724.7.RosenLS(2002)Clinicalexperiencewithangiogenesissignalinginhibitors:focusonvascularendothelialgrowthfactor(VEGF)blockers.CancerControl9:36244.8.FerraraN,HillanKJ,GerberHP,NovotnyW(2004)Discoveryanddevelopmentofbevacizumab,ananti-VEGFantibodyfortreatingcancer.NatRevDrugDiscov3:3912400.9.PlotkinSR,Stemmer-RachamimovAO,BarkerFG,HalpinC,PaderaTP,etal.(2009)Hearingimprovementafterbevacizumabinpatientswithneurofibroma-tosistype2.NEnglJMed361:3582367.10.GoutagnyS,RaymondE,SterkersO,ColombaniJM,KalamaridesM(2011)RadiographicregressionofcranialmeningiomainaNF2patienttreatedbybevacizumab.AnnOncol22:9902991.11.PuchnerMJ,HansVH,HaratiA,LohmannF,GlasM,etal.(2010)Bevacizumab-inducedregressionofanaplasticmeningioma.AnnOncol21:244522446.12.LouE,SumrallAL,TurnerS,PetersKB,DesjardinsA,etal.(2012)Bevacizumabtherapyforadultswithrecurrent/progressivemeningioma:aretrospectiveseries.JNeurooncol109:63270.13.NayakL,IwamotoFM,RudnickJD,NordenAD,LeeEQ,etal.(2012)Atypicalandanaplasticmeningiomastreatedwithbevacizumab.JNeurooncol109:1872193.14.GoodwinJW,CrowleyJ,EyreHJ,StaffordB,JaeckleKA,etal.(1993)AphaseIIevaluationoftamoxifeninunresectableorrefractorymeningiomas:aSouthwestOncologyGroupstudy.JNeurooncol15:75277.15.ChamberlainMC,Tsao-WeiDD,GroshenS(2006)SalvagechemotherapywithCPT-11forrecurrentmeningioma.JNeurooncol78:2712276.16.ChamberlainMC,Tsao-WeiDD,GroshenS(2004)Temozolomidefortreatment-resistantrecurrentmeningioma.Neurology62:121021212.17.JohnsonDR,KimmelDW,BurchPA,CascinoTL,GianniniC,etal.(2011)PhaseIIstudyofsubcutaneousoctreotideinadultswithrecurrentorprogressivemeningiomaandmeningealhemangiopericytoma.NeuroOncol13:5302535.18.SchulzC,MathieuR,KunzU,MauerUM(2011)Treatmentofunresectableskullbasemeningiomaswithsomatostatinanalogs.NeurosurgFocus30:E11.19.GrunbergSM,WeissMH,RussellCA,SpitzIM,AhmadiJ,etal.(2006)Long-termadministrationofmifepristone(RU486):clinicaltoleranceduringextendedtreatmentofmeningioma.CancerInvest24:7272733.20.NordenAD,RaizerJJ,AbreyLE,LambornKR,LassmanAB,etal.(2009)PhaseIItrialsoferlotiniborgefitinibinpatientswithrecurrentmeningioma.JNeurooncol.21.WenPY,YungWK,LambornKR,NordenAD,CloughesyTF,etal.(2009)PhaseIIstudyofimatinibmesylateforrecurrentmeningiomas(NorthAmericanBrainTumorConsortiumstudy01208).NeuroOncol11:8532860.22.ChamberlainMC,GlantzMJ(2008)Interferon-alphaforrecurrentWorldHealthOrganizationgrade1intracranialmeningiomas.Cancer113:214622151.23.KabaSE,DeMonteF,BrunerJM,KyritsisAP,JaeckleKA,etal.(1997)Thetreatmentofrecurrentunresectableandmalignantmeningiomaswithinterferonalpha-2B.Neurosurgery40:2712275.24.SchrellUM,RittigMG,AndersM,KochUH,MarschalekR,etal.(1997)Hydroxyureafortreatmentofunresectableandrecurrentmeningiomas.II.Decreaseinthesizeofmeningiomasinpatientstreatedwithhydroxyurea.JNeurosurg86:8402844.25.LovenD,HardoffR,SeverZB,SteinmetzAP,GornishM,etal.(2004)Non-resectableslow-growingmeningiomastreatedbyhydroxyurea.JNeurooncol67:2212226.26.MasonWP,GentiliF,MacdonaldDR,HariharanS,CruzCR,etal.(2002)Stabilizationofdiseaseprogressionbyhydroxyureainpatientswithrecurrentorunresectablemeningioma.JNeurosurg97:3412346.27.EisenhauerEA,TherasseP,BogaertsJ,SchwartzLH,SargentD,etal.(2009)Newresponseevaluationcriteriainsolidtumours:revisedRECISTguideline(version1.1).EurJCancer45:2282247.28.PlotkinSR,MerkerVL,HalpinC,JenningsD,McKennaMJ,etal.(2012)Bevacizumabforprogressivevestibularschwannomainneurofibromatosistype2:aretrospectivereviewof31patients.OtolNeurotol33:104621052.BevacizumabTreatmentforMeningiomasinNF2PLOSONE|www.plosone.org8March2013|Volume8|Issue3|e59941